Replies to post #236952 on Biotech Values

[DewDiligence]

ENTA investors appear pleased with ABBV’s $2.0B guidance for 2021 Mavyret sales (#msg-161451655). As has been discussed on this board ad nauseam, Mavyret will not have positive growth, but it should have a long tail.